DexCom, Inc. (NASDAQ:DXCM) is one of the 12 High Quality Stocks to Buy for the Long Term. On June 15, 2026, Piper Sandler ...

BofA raised the firm’s price target on DexCom (DXCM) to $90 from $80 and keeps a Buy rating on the shares post the Q3 report. DexCom did a good job instilling confidence in its 2025 revenue target ...

DexCom (NASDAQ:DXCM) stock saw a notable increase of 16% on Friday following the announcement of its Q1 earnings and a share buyback program. The company’s first-quarter sales hit $1.04 billion, ...

DexCom is a leader in the continuous glucose monitoring (CGM) systems market. They aren't the only kinds of devices that help diabetes patients keep track of their blood glucose levels -- a necessary ...

Insulet Corporation (PODD) and DexCom (DXCM) were among notable gainers in MedTech on Tuesday after Deutsche Bank initiated the diabetes device makers with Buy ratings despite their sharp sell-off in ...

DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...

DexCom, Inc. DXCM reported better-than-expected third-quarter results on Thursday. DexCom reported quarterly earnings of 45 cents per share, which beat the analyst consensus estimate of 43 cents.

There's been a huge drop-off in DexCom's growth rate of late, and that's a key reason investors believe that there may be a strong correlation between rising GLP-1 use and demand for CGMs. The company ...

It's been a tough year for DexCom (NASDAQ: DXCM), whose stock price is down 25% since the start of 2025. It's a surprising performance, given that the overall stock market has been doing well; you ...